Sentara Health Enrolls Participants in National Study on Multi-Cancer Detection Tests

Strategic Insights -

Sentara Health is partnering with a national network of researchers to study the effectiveness of Multi-Cancer Detection (MCD) tests in detecting various cancer types. The Vanguard Study, a part of the Cancer Screening Research Network (CSRN), aims to evaluate whether these blood tests can help identify cancers early when they may be easier to treat. The study will recruit adults aged 45 to 75 with no cancer diagnosis in the past five years to participate in a pivotal study evaluating the Avantect MCD Test by ClearNote Health and the Shield MCD Test by Guardant Health.

Key Takeaways:

  • The Vanguard Study is a national study evaluating the effectiveness of Multi-Cancer Detection (MCD) tests in detecting various cancer types, including bladder, breast, colorectal, esophageal, stomach, liver, lung, ovarian, pancreatic, and prostate cancers.
  • The study is part of the Cancer Screening Research Network (CSRN), a new national network of primary care sites devoted to cancer screening research funded by the National Cancer Institute (NCI).
  • Participants will give two blood samples and complete regular cancer screening as recommended by clinicians.
  • The study will evaluate two MCD tests: Avantect MCD Test by ClearNote Health and the Shield MCD Test by Guardant Health.
  • Participants will be randomized to one of three arms: two MCD arms where their blood will be tested by an MCD test or a control arm where the blood will be stored for potential future research.
  • The Vanguard Study aims to provide information on how MCD tests work as cancer screening tools and explore the decisions that patients and their doctors make based on their results.
  • Sentara Health is recruiting participants for the study, and interested individuals can visit [https://www.virginiacsrn.org](https://www.virginiacsrn.org), call 757-765-7780, or email [vanguard@sentara.com](mailto:vanguard@sentara.com) to learn more about the study and eligibility to participate.

Statistics:

  • The study will recruit adults aged 45 to 75 with no cancer diagnosis in the past five years.
  • The study will evaluate two MCD tests: Avantect MCD Test by ClearNote Health and the Shield MCD Test by Guardant Health.
  • Participants will give two blood samples and complete regular cancer screening as recommended by clinicians.
  • The study aims to recruit 10,000 participants across the United States.

Sources:

  • "Sentara now enrolling participants in national study of blood tests designed to detect multiple cancer types." (Source: Sentara)
  • National Cancer Institute (NCI)
  • Cancer Screening Research Network (CSRN)